Views

Abstract: 1550

PDF (English): 627

Cited-by

1. Liang X, Dai J, Wang F. Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis. BMC Cardiovascular Disorders. 2025;25(1). doi: 10.1186/s12872-024-04442-5
2. Yang X, Lin R, Feng C, Kang Q, Yu P, Deng Y, et al. Research Progress on Peptide Drugs for Type 2 Diabetes and the Possibility of Oral Administration. Pharmaceutics. 2024;16(11):1353. doi: 10.3390/pharmaceutics16111353
3. Karakasis P, Patoulias D, Kassimis G, Koufakis T, Klisic A, Doumas M, et al. Therapeutic Potential of Sodium-glucose Co-transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists for Patients with Acute Coronary Syndrome: A Review of Clinical Evidence. Current Pharmaceutical Design. 2024;30(27):2109. doi: 10.2174/0113816128304097240529053538
4. Patoulias D, Karakasis P, Rangraze I, El-Tanani M, Rizzo M. Beneficial effects of SGLT-2 inhibitors on cardiac autonomic function: surprises never end!. Journal of Diabetes and its Complications. 2025;:109113. doi: 10.1016/j.jdiacomp.2025.109113
5. Adare AF, Tiyare FT, Marine BT. Time to development of macrovascular complications and its predictors among type 2 diabetes mellitus patients at Jimma University Medical Center. BMC Endocrine Disorders. 2024;24(1). doi: 10.1186/s12902-024-01782-3